Assoc Dir, Acute Therapies - OST

Vantive•Deerfield, IL

1d•$172,000 - $215,000

About The Position

Vantive is a vital organ therapy company on a mission to extend lives and expand possibilities for patients and care teams everywhere. For 70 years, our team has driven meaningful innovations in kidney care. As we build on our legacy, we are deepening our commitment to elevating the dialysis experience through digital solutions and advanced services, while looking beyond kidney care and investing in transforming vital organ therapies. Greater flexibility and efficiency in therapy administration for care teams, and longer, fuller lives for patients— that is what Vantive aspires to deliver. We believe Vantive will not only build our leadership in the kidney care space, it will also offer meaningful work to those who join us. At Vantive, you will become part of a community of people who are focused, courageous and don’t settle for the mediocre. Each of us is driven to help improve patients’ lives worldwide. Join us in advancing our mission to extend lives and expand possibilities. Your role at Vantive The Global Associate Director, Immune Dysregulation & Acute Liver Failure Therapies & Products is responsible for helping shape global strategy and leading execution to accelerate growth across Vantive’s current on-market and future new product development portfolio within Immune Dysregulation and Acute Liver Failure. Reporting to the Sr. Director, Global Organ Support Therapies, this role partners closely on portfolio priorities and translates them into integrated evidence, reimbursement, lifecycle, and commercialization plans that expand access, increase utilization, and strengthen long-term value creation across diverse geographies. This is a highly visible opportunity to lead within strategically important therapy areas at the intersection of critical care, innovation, market development, and global commercial execution. Success requires strong prioritization, matrix leadership, and the ability to drive meaningful results with a lean, high-impact team. Reporting to the Sr. Director, Global Organ Support Therapies, this position leads a small global team (1 direct report) and serves as a highly visible connector across a deeply matrixed cross-functional network including Medical Affairs, Clinical, HEOR/Market Access, Regulatory, Quality, R&D, Commercial Excellence, Digital, Finance, Supply Chain, and BD&L as needed. The Sr. Director owns overall portfolio strategy, while the Global Associate Director contributes materially to strategy development and owns cross-functional execution for the Immune Dysregulation and Acute Liver Failure therapies and products portfolio across both existing commercial offerings and future pipeline/NPD programs. This role is well suited for a leader who thrives in complexity, enjoys building from opportunity, and wants broad exposure across strategy, innovation, and execution in globally relevant critical care spaces.

Requirements

BS/BA required; advanced degree (MBA, MSc, MPH) preferred.
Minimum 8–10 years of experience in medical device/pharma/healthcare, including 3+ years in global portfolio, product management, or commercialization roles, with demonstrated readiness for broader strategic leadership.
Demonstrated success supporting growth of therapies and products through strong implementation, evidence and access planning, launch readiness, and field enablement to unlock adoption across Immune Dysregulation, Acute Liver Failure, or related critical care spaces.
Experience partnering with Medical Affairs/Clinical on evidence generation, and with Market Access/HEOR on reimbursement and value demonstration across multiple geographies.
Track record of leading cross-functional teams in a global matrix and influencing regional/country stakeholders without direct authority, with credibility across both strategic and operational discussions.
Background in acute/critical care preferred, with meaningful exposure to Immune Dysregulation, Acute Liver Failure, sepsis, and related ICU care pathways.
Demonstrated ability to connect clinical, economic, and market inputs into actionable implementation plans that drive adoption and profitable growth.
Proven experience in therapies and products management, lifecycle marketing, commercialization, or upstream/downstream portfolio roles for medical devices or critical care therapies, including positioning, segmentation, evidence translation, and barrier-based growth programs.
Working knowledge of evidence generation and publication strategy, HEOR concepts, and reimbursement/market access pathways across major global regions.
Strong business acumen with experience developing business cases for market prioritization, footprint/archetype decisions, pricing and contracting choices, tender dynamics, and value optimization across heterogeneous country landscapes.
Exceptional analytical and problem‑solving skills; able to translate data into decisions, prioritize ruthlessly, and manage tradeoffs in a resource‑constrained environment.
Excellent communication skills and executive presence, with the ability to influence senior stakeholders, translate complexity into clear direction, and represent the business effectively across global forums.
Ability to operate with agility in fast‑changing environments, maintaining compliance and quality while driving speed and impact.

Responsibilities

Partner with the Sr. Director on strategy development and own execution of the annual operating plan for the Immune Dysregulation and Acute Liver Failure therapies and products portfolio, translating strategic priorities across current on-market and future NPD offerings into measurable growth objectives and workplans.
Develop business cases and strategic recommendations to determine priority markets, expansion sequencing, and the right archetype footprint models for the therapies and products in scope, balancing market attractiveness, evidence readiness, access potential, resource requirements, and long-term value creation.
Identify adoption barriers by segment (clinical pathway, workflow, protocol inclusion, training, economic value, procurement, competitive alternatives) and implement targeted interventions to unlock penetration.
Own and maintain a global lifecycle roadmap aligned to portfolio strategy by sequencing evidence, market access, pricing, education, commercialization, and launch-readiness initiatives across commercialized therapies and future pipeline/NPD products to expand footprint and utilization over time.
Develop and support portfolio positioning, value proposition architecture, and core messaging across Immune Dysregulation and Acute Liver Failure therapies and products that are clinically credible and economically defensible, enabling a consistent global narrative with local adaptability.
Coordinate cross‑functional execution across functions to align priorities, manage dependencies, and ensure disciplined delivery against timelines, deliverables, and budget.
Partner with regional and country counterparts to co‑develop country growth plans that reflect differences in installed base, clinical practice patterns, tendering/procurement dynamics, and reimbursement pathways.
Own governance for portfolio performance (KPIs, leading indicators, pipeline of initiatives, risk register) and drive corrective actions when adoption or profitability deviates from plan, escalating key decisions as appropriate.
Identify and evaluate high‑value expansion opportunities (new indications/labels where appropriate, new care settings, channel/partner options, geographic expansion) and collaborate with BD&L on execution.
Partner on the design and execution of integrated evidence generation plans for on-market therapies and future NPD programs (clinical, real-world evidence/registries, health economics, and outcomes research) that address the highest adoption, access, and launch barriers across Immune Dysregulation and Acute Liver Failure.
Partner with Medical Affairs and Clinical to prioritize studies, publications, congress strategy, and KOL engagement plans that strengthen clinical credibility and accelerate protocol inclusion.
Partner with HEOR/Market Access and regions to support a global reimbursement and value dossier roadmap (claims, endpoints, economic models, budget impact tools) that enables country‑specific access strategies.
Drive barrier‑removal initiatives across the adoption funnel: disease/therapy awareness, patient identification and pathway integration, education and competency building, and institutional protocol development.
Develop global playbooks and toolkits for clinical education (in‑person and digital) that regions can localize while preserving scientific accuracy, regulatory compliance, and brand consistency.
Collaborate with external societies and internal stakeholders to support inclusion in relevant guidelines, pathways, and hospital protocols where appropriate and evidence‑supported.
Support the global go-to-market and launch-readiness framework for current and future therapies and products, including segmentation, positioning, core messages, evidence translation, and adoption pathways aligned to regional and country execution models.
Support portfolio performance management across countries with different footprints, helping identify the right growth levers by market (pricing, contracting/tenders, channel strategy, training, protocol inclusion, KOL activation, and service model).
Partner on global pricing and value optimization strategy with regions, Finance, and Market Access—helping establish guardrails, value-based narratives, and decision support to balance growth and profitability.
Support portfolio investment planning and budget management, ensuring resources are directed to the highest-impact evidence, access, and adoption initiatives with clear ROI hypotheses.
Build scalable implementation playbooks that translate evidence into practical adoption for Immune Dysregulation and Acute Liver Failure therapies and products, including patient identification, workflow integration, training pathways, protocol templates, launch readiness, and success metrics.
Coordinate cross‑functional readiness for geographic expansion and footprint growth, including supply planning, service model alignment, labeling/claims alignment, and country launch sequencing for on‑market products.
Drive post‑implementation learning loops with regions and countries to codify best practices, address variability in ICU practice patterns, and improve adoption velocity over time.
Drive post‑implementation learning loops with regions and countries to codify best practices, address variability in ICU practice patterns, and improve adoption velocity over time.
Lead and develop a small global team (1 direct report) with clear priorities, high standards, and strong coaching, while setting the operating tempo for disciplined execution across the broader matrix.
Establish a pragmatic operating rhythm (quarterly planning, monthly performance reviews, cross‑functional workstream cadences) to drive alignment and accountability across the matrix.
Influence without authority by aligning stakeholders on shared outcomes, clarifying tradeoffs, and resolving conflicts across functions, regions, and countries.
Build and maintain strong relationships with KOLs, clinical champions, health economists, and industry partners to enhance credibility and accelerate adoption.
Model a “strategy + sleeves rolled up” leadership style—balancing high‑level direction with hands‑on contribution to critical deliverables in a lean team environment.